7 research outputs found
Les Pertes Economiques Dues A L’anthracnose De L’anacardier Au Bénin
Anthracnose caused by Colletotrichum gloeosporioides is a disease that causes losses of cashew production in Benin. This study aims to evaluate the economic losses in cashew nuts caused by the disease. The data were collected using a questionary on a sample of 84 farmers from 12 villages in Savè (Centre of Benin) and 126 farmers from 13 villages in N'Dali (North of Benin). These data included socio-demographic characteristics of the respondent, anthracnose expression, disease management methods, yield losses, cashew nut yield, and sale price per kg of cashew nuts. In Savè and N’Dali, 98.68% and 100% of farmers, respectively, reported the presence of anthracnose in their plantations. The yield losses were 316.95 kg/ha (72.19%) at Savè and 189.01 kg/ha (54.71%) at N’Dali. In the period of low demand, these losses amounted an average of 68061 FCFA/ha/farmer at Savè and 42316 FCFA/ha/farmer at N'Dali, while in the high demand periods, they were evaluated to 221576 FCFA/ha/farmer and 135339 FCFA/ha/farmer at Savè and at N'Dali, respectively
Essential Medicines at the National Level : The Global Asthma Network's Essential Asthma Medicines Survey 2014
Patients with asthma need uninterrupted supplies of affordable, quality-assured essential medicines. However, access in many low- and middle-income countries (LMICs) is limited. The World Health Organization (WHO) Non-Communicable Disease (NCD) Global Action Plan 2013-2020 sets an 80% target for essential NCD medicines' availability. Poor access is partly due to medicines not being included on the national Essential Medicines Lists (EML) and/or National Reimbursement Lists (NRL) which guide the provision of free/subsidised medicines. We aimed to determine how many countries have essential asthma medicines on their EML and NRL, which essential asthma medicines, and whether surveys might monitor progress. A cross-sectional survey in 2013-2015 of Global Asthma Network principal investigators generated 111/120 (93%) responses41 high-income countries and territories (HICs); 70 LMICs. Patients in HICs with NRL are best served (91% HICs included ICS (inhaled corticosteroids) and salbutamol). Patients in the 24 (34%) LMICs with no NRL and the 14 (30%) LMICs with an NRL, however no ICS are likely to have very poor access to affordable, quality-assured ICS. Many LMICs do not have essential asthma medicines on their EML or NRL. Technical guidance and advocacy for policy change is required. Improving access to these medicines will improve the health system's capacity to address NCDs.Peer reviewe
Essential Medicines at the National Level: The Global Asthma Network's Essential Asthma Medicines Survey 2014
10.3390/ijerph16040605INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH16
Essential medicines at the National Level : the Global Asthma Network's Essential Asthma Medicines Survey 2014
Global Asthma Network survey suggests more national asthma strategies could reduce burden of asthma
Background Several countries or regions within countries have an effective national asthma strategy resulting in a reduction of the large burden of asthma to individuals and society. There has been no systematic appraisal of the extent of national asthma strategies in the world. Methods The Global Asthma Network (GAN) undertook an email survey of 276 Principal Investigators of GAN centres in 120 countries, in 2013–2014. One of the questions was: “Has a national asthma strategy been developed in your country for the next five years? For children? For adults?”. Results Investigators in 112 (93.3%) countries answered this question. Of these, 26 (23.2%) reported having a national asthma strategy for children and 24 (21.4%) for adults; 22 (19.6%) countries had a strategy for both children and adults; 28 (25%) had a strategy for at least one age group. In countries with a high prevalence of current wheeze, strategies were significantly more common than in low prevalence countries (11/13 (85%) and 7/31 (22.6%) respectively, p < 0.001). Interpretation In 25% countries a national asthma strategy was reported. A large reduction in the global burden of asthma could be potentially achieved if more countries had an effective asthma strategy. © 2017 SEICA
Global Asthma Network survey suggests more national asthma strategies could reduce burden of asthma
Background Several countries or regions within countries have an effective national asthma strategy resulting in a reduction of the large burden of asthma to individuals and society. There has been no systematic appraisal of the extent of national asthma strategies in the world. Methods The Global Asthma Network (GAN) undertook an email survey of 276 Principal Investigators of GAN centres in 120 countries, in 2013–2014. One of the questions was: “Has a national asthma strategy been developed in your country for the next five years? For children? For adults?”. Results Investigators in 112 (93.3%) countries answered this question. Of these, 26 (23.2%) reported having a national asthma strategy for children and 24 (21.4%) for adults; 22 (19.6%) countries had a strategy for both children and adults; 28 (25%) had a strategy for at least one age group. In countries with a high prevalence of current wheeze, strategies were significantly more common than in low prevalence countries (11/13 (85%) and 7/31 (22.6%) respectively, p < 0.001). Interpretation In 25% countries a national asthma strategy was reported. A large reduction in the global burden of asthma could be potentially achieved if more countries had an effective asthma strategy. © 2017 SEICA